Renovos secures FDA breakthrough status for bone graft alternative

MedTech Dive January 5, 2024
Nick Paul Taylor

When injected, Renovite acts as a scaffold for cells and helps localize and retain molecules that stimulate healing.

Dive Brief:

• Renovos Biologics has received breakthrough designation for a synthetic nanoclay gel scaffold designed to support localized bone formation.
• The Food and Drug Administration granted breakthrough status to a product, Renovite BMP-2, that Renovos sees as an alternative to bone graft materials for interbody spinal fusion.
• Medtech company Biocomposites invested in Renovos last year to help fund pre-market approval in spine, trauma and orthopedics applications.

Dive Insight:

When injected, Renovite acts as a scaffold for cells and helps localize and retain molecules that stimulate healing, according to Renovos. The properties of the gel led the company to use it...

Today's Sponsors

Today's Sponsor